Altfest L J & Co. Inc. Reduces Stock Position in Humana Inc. (NYSE:HUM)

Altfest L J & Co. Inc. reduced its position in shares of Humana Inc. (NYSE:HUMFree Report) by 28.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 701 shares of the insurance provider’s stock after selling 283 shares during the period. Altfest L J & Co. Inc.’s holdings in Humana were worth $321,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Sunbelt Securities Inc. bought a new position in shares of Humana during the first quarter valued at approximately $28,000. Baystate Wealth Management LLC boosted its stake in shares of Humana by 84.1% during the 2nd quarter. Baystate Wealth Management LLC now owns 81 shares of the insurance provider’s stock worth $37,000 after acquiring an additional 37 shares during the last quarter. Householder Group Estate & Retirement Specialist LLC purchased a new position in shares of Humana during the 3rd quarter valued at $39,000. Nvwm LLC lifted its stake in shares of Humana by 41.0% during the 3rd quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock valued at $42,000 after buying an additional 25 shares in the last quarter. Finally, Operose Advisors LLC purchased a new position in shares of Humana during the 3rd quarter valued at $56,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Down 0.8 %

HUM stock opened at $346.72 on Friday. Humana Inc. has a twelve month low of $334.54 and a twelve month high of $541.21. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $41.83 billion, a P/E ratio of 17.49, a PEG ratio of 2.04 and a beta of 0.45. The firm has a 50 day simple moving average of $362.42 and a 200-day simple moving average of $442.64.

Humana (NYSE:HUMGet Free Report) last released its quarterly earnings data on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.87). The business had revenue of $26.46 billion during the quarter, compared to analyst estimates of $25.47 billion. Humana had a return on equity of 19.44% and a net margin of 2.34%. The business’s revenue for the quarter was up 17.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.62 EPS. On average, equities research analysts predict that Humana Inc. will post 16.04 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Friday, March 29th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.02%. The ex-dividend date of this dividend is Wednesday, March 27th. Humana’s dividend payout ratio (DPR) is 17.86%.

Insider Activity at Humana

In related news, Director Jorge S. Mesquita acquired 545 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were acquired at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the purchase, the director now directly owns 2,578 shares in the company, valued at $946,358.02. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Stephens reduced their target price on shares of Humana from $550.00 to $430.00 and set an “overweight” rating on the stock in a report on Friday, January 26th. The Goldman Sachs Group lowered their target price on shares of Humana from $515.00 to $450.00 and set a “buy” rating for the company in a research note on Friday, January 26th. Truist Financial restated a “hold” rating and issued a $550.00 target price on shares of Humana in a research note on Friday, January 19th. Raymond James assumed coverage on shares of Humana in a report on Friday, March 22nd. They issued a “market perform” rating for the company. Finally, Royal Bank of Canada decreased their price target on shares of Humana from $507.00 to $415.00 and set an “outperform” rating for the company in a report on Friday, January 26th. Ten equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $494.00.

Read Our Latest Stock Analysis on HUM

Humana Profile

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.